Novo Nordisk A/S (
) will begin trading ex-dividend on March 21, 2013. A cash dividend
payment of $3.1838 per share is scheduled to be paid on April 02,
2013. Shareholders who purchased NVO stock prior to the ex-dividend
date are eligible for the cash dividend payment. This represents an
27.51% increase over the prior year.
The previous trading day's last sale of NVO was $166.45,
representing a -14.4% decrease from the 52 week high of $194.44 and
a 28.63% increase over the 52 week low of $129.41.
NVO is a part of the Consumer Durables sector, which includes
companies such as Johnson & Johnson (
) and Pfizer, Inc. (
). NVO's current earnings per share, an indicator of a company's
profitability, is $6.8. Zacks Investment Research reports NVO's
forecasted earnings growth in 2013 as 15.66%, compared to an
industry average of -.1%.
For more information on the declaration, record and payment
dates, visit the
Interested in gaining exposure to NVO through an Exchange
Traded Fund [ETF]?
The following ETF(s) have NVO as a top-10 holding:
- Merrill Lynch Pharmaceutical HOLDRS (
- WCM BNY Mellon Focused Growth ADR ETF (
- Columbia Select Large Cap Growth ETF (
- Direxion Developed Markets Bull 3x Shares (
- BLDRS Europe 100 ADR Index Fund (
The top-performing ETF of this group is DZK with an increase of
26.09% over the last 100 days. PPH has the highest percent
weighting of NVO at 4.67%.